Advance Pharmaceutical Initiates Enrollment for HTI-320 Clinical Trial

Advance Pharmaceutical of Hong Kong initiate enrollment for the clinical trial of BTI-320, also known as Sugardown® , at the Chinese University of Hong Kong (CUHK). The clinical trial is expected to enrol 60 pre-diabetic patients and is a single-center, 16-week, randomized, double-blind pilot study designed to evaluate the efficacy and safety of BTI-320 in the treatment of high risk subjects with pre-diabetes. It is supplemental to an on-going separate clinical trial being conducted in mainland China. More details.... Share this with colleagues: // //   references